https://www.nasdaq.com/press-release/oncolytics-biotech-reports-2018-second-quarter-results-20180803-00248
They recently listed on the Nasdaq and don’t seem to meet either of the criteria you listed. I’m not sure if there are exemptions available?
They did do a share rollback and a capital raise concurrent with their listing.
I expect you’ll be right but think Don may want to have us on the Nasdaq prior to the release of topline results.
bfw